Health & Fitness
Mon, January 30, 2012
NEW YORK--([ BUSINESS WIRE ])--Harwood Feffer LLP ([ www.hfesq.com ]) is investigating potential claims against the board of directors of Micromet, Inc. (aMicrometa or the aCompanya) (NASDAQ: MITI) concerning the proposed acquisition of the Company by Amgen, Inc. (aAmgena) in a transaction valued at approximately $1.16 billion.
On January 26, 2012, Micromet and Amgen announced that they have entered into a definitive merger agreement pursuant to which Amgen will acquire Micromet for $11 per share in cash. At least one analyst has set a price target of $12.00 per share for Micromet stock.
Our investigation concerns whether the board of directors is fulfilling its fiduciary duties, maximizing the value of Micromet, disclosing all material benefits and costs and obtaining full and fair consideration for Micromet shareholders.
If you own Micromet shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin Sachs-Michaels
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: [ bsachsmichaels@hfesq.com ]
Website: [ http://www.hfesq.com ]
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ([ http://www.hfesq.com ]) for more information about the firm.
Attorney Advertising. 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ([ www.hfesq.com ]). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
